ArticleOncoimmunology2020

An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial.

Julie Charles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.